Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Return on Capital Employed (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Return on Capital Employed data on record, last reported at 0.55% in Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 29.0% year-over-year to 0.55%; the TTM value through Dec 2025 reached 0.55%, up 29.0%, while the annual FY2025 figure was 0.47%, 33.0% up from the prior year.
  • Return on Capital Employed reached 0.55% in Q4 2025 per ACRS's latest filing, up from 0.98% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.3% in Q3 2024 and bottomed at 0.98% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.52%, with a median of 0.49% recorded in 2024.
  • Peak YoY movement for Return on Capital Employed: soared 66bps in 2021, then tumbled -68bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.38% in 2021, then increased by 2bps to 0.38% in 2022, then tumbled by -46bps to 0.55% in 2023, then crashed by -52bps to 0.84% in 2024, then surged by 34bps to 0.55% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.55% in Q4 2025, 0.98% in Q3 2025, and 0.88% in Q2 2025.